Penicillin binding proteins

Ended Definitive Contract Awarded Last action

Contract number
HDTRA117C0070
Awardee
Awarding agency
Obligated
$14,256,515

Award facts

Contract value 71% obligated
  • $14,716,732.53 Current, with exercised options
  • $19,969,099.47 Potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 3 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Malvern, PA 19355, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00013 $0
Funding Only Action P00012 · New PBP inhibitors impervious to beta-lactamases -$460,217
Funding Only Action P00011 · Penicillin binding protein inhibitors impervious to beta lactamases $1,915,975
Supplemental Agreement for work within scope P00010 · Research & development services - new penicillin binding protein (PBP) inhibitors impervious to beta- lactamases $1,048,218
Supplemental Agreement for work within scope P00009 $0
Supplemental Agreement for work within scope P00008 · The purpose of this modification is to add value and funding for a cost overrun. $1,040,730
Supplemental Agreement for work within scope P00007 $0
Funding Only Action P00006 $1,856,630
Funding Only Action P00005 $1,281,875
Exercise an Option P00004 $2,500,000
Supplemental Agreement for work within scope P00003 $1,373,305
Funding Only Action P00002 $2,600,000
Funding Only Action P00001 · Penicillin binding protein inhibitors impervious to beta lactamases $400,000
Original award $700,000
Show all 14

About this award

The Defense Threat Reduction Agency awarded a definitive contract to Venatorx Pharmaceuticals Inc. for penicillin binding protein inhibitors impervious to beta-lactamases, with a ceiling value of $19,969,099.47, on August 28, 2017. The contract operated under cost-plus-fixed-fee pricing and concluded on October 27, 2023. Place of performance is Malvern, PA.

Quick answers

Who was awarded contract HDTRA117C0070?

HDTRA117C0070 was awarded to Venatorx Pharmaceuticals Inc. by Defense Threat Reduction Agency (Department of Defense) on August 28, 2017.

How much is contract HDTRA117C0070 worth?

The government has obligated $14,256,515 on HDTRA117C0070. Its current value, with exercised options, is $14,716,733. Its potential value, with all options, is $19,969,099.

Was contract HDTRA117C0070 competed?

The extent of competition for HDTRA117C0070 was full and open competition. The government received 3 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award